Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antisense oligonucleotides - Stoke Therapeutics

Next Previous
Drug Profile

Research programme: antisense oligonucleotides - Stoke Therapeutics

Alternative Names: TANGO ASO

Latest Information Update: 28 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stoke Therapeutics
  • Class Antiepileptic drugs; Antisense oligonucleotides; Eye disorder therapies; Hepatoprotectants; Neuroprotectants
  • Mechanism of Action Methyl-CpG-binding protein 2 expression stimulants; NAV1.1 voltage-gated sodium channel modulators; RNA interference; SYNGAP1 protein expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dravet syndrome; Haematological disorders; Liver disorders; Neurological disorders; Optic atrophy; Rett syndrome

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for preclinical development in Dravet-syndrome in USA
  • 28 Mar 2024 No recent reports of development identified for preclinical development in Neurological-disorders in USA
  • 31 Dec 2023 Antisense oligonucleotides is still in for preclinical development in Liver-disorders in USA (SEC filling, December 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top